JP2014504630A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014504630A5 JP2014504630A5 JP2013552292A JP2013552292A JP2014504630A5 JP 2014504630 A5 JP2014504630 A5 JP 2014504630A5 JP 2013552292 A JP2013552292 A JP 2013552292A JP 2013552292 A JP2013552292 A JP 2013552292A JP 2014504630 A5 JP2014504630 A5 JP 2014504630A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- layer
- weight
- agonist
- naltrexone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 claims 23
- 229960003086 naltrexone Drugs 0.000 claims 17
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims 17
- 239000011248 coating agent Substances 0.000 claims 12
- 238000000576 coating method Methods 0.000 claims 12
- 239000000556 agonist Substances 0.000 claims 11
- 239000005557 antagonist Substances 0.000 claims 11
- 239000003402 opiate agonist Substances 0.000 claims 11
- 229920000642 polymer Polymers 0.000 claims 11
- ZFSXKSSWYSZPGQ-UHFFFAOYSA-N (2-hydroxycyclopentyl)azanium;chloride Chemical compound Cl.NC1CCCC1O ZFSXKSSWYSZPGQ-UHFFFAOYSA-N 0.000 claims 6
- 239000002552 dosage form Substances 0.000 claims 6
- 229960000858 naltrexone hydrochloride Drugs 0.000 claims 6
- BQNSLJQRJAJITR-UHFFFAOYSA-N 1,1,2-trichloro-1,2-difluoroethane Chemical compound FC(Cl)C(F)(Cl)Cl BQNSLJQRJAJITR-UHFFFAOYSA-N 0.000 claims 4
- 230000014759 maintenance of location Effects 0.000 claims 4
- 229960003617 oxycodone hydrochloride Drugs 0.000 claims 4
- 238000013270 controlled release Methods 0.000 claims 3
- 239000008188 pellet Substances 0.000 claims 3
- 230000036470 plasma concentration Effects 0.000 claims 3
- 208000000094 Chronic Pain Diseases 0.000 claims 2
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical group O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 229960002085 oxycodone Drugs 0.000 claims 2
- 239000008363 phosphate buffer Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161438882P | 2011-02-02 | 2011-02-02 | |
| US61/438,882 | 2011-02-02 | ||
| PCT/IB2012/050348 WO2012104752A1 (en) | 2011-02-02 | 2012-01-25 | Pharmaceutical composition comprising opioid agonist and sequestered antagonist |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016237476A Division JP2017081942A (ja) | 2011-02-02 | 2016-12-07 | オピオイドアゴニストおよび隔離されているアンタゴニストを含む医薬組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014504630A JP2014504630A (ja) | 2014-02-24 |
| JP2014504630A5 true JP2014504630A5 (cg-RX-API-DMAC7.html) | 2015-03-05 |
Family
ID=45607315
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013552292A Withdrawn JP2014504630A (ja) | 2011-02-02 | 2012-01-25 | オピオイドアゴニストおよび隔離されているアンタゴニストを含む医薬組成物 |
| JP2016237476A Withdrawn JP2017081942A (ja) | 2011-02-02 | 2016-12-07 | オピオイドアゴニストおよび隔離されているアンタゴニストを含む医薬組成物 |
| JP2018040441A Pending JP2018109059A (ja) | 2011-02-02 | 2018-03-07 | オピオイドアゴニストおよび隔離されているアンタゴニストを含む医薬組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016237476A Withdrawn JP2017081942A (ja) | 2011-02-02 | 2016-12-07 | オピオイドアゴニストおよび隔離されているアンタゴニストを含む医薬組成物 |
| JP2018040441A Pending JP2018109059A (ja) | 2011-02-02 | 2018-03-07 | オピオイドアゴニストおよび隔離されているアンタゴニストを含む医薬組成物 |
Country Status (14)
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6696088B2 (en) | 2000-02-08 | 2004-02-24 | Euro-Celtique, S.A. | Tamper-resistant oral opioid agonist formulations |
| US20110104214A1 (en) | 2004-04-15 | 2011-05-05 | Purdue Pharma L.P. | Once-a-day oxycodone formulations |
| AU2011232408B2 (en) | 2010-03-24 | 2015-07-30 | Jazz Pharmaceuticals, Inc. | Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances |
| US10398662B1 (en) | 2015-02-18 | 2019-09-03 | Jazz Pharma Ireland Limited | GHB formulation and method for its manufacture |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12478604B1 (en) | 2016-07-22 | 2025-11-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US20180263936A1 (en) | 2017-03-17 | 2018-09-20 | Jazz Pharmaceuticals Ireland Limited | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
| CN111629758A (zh) * | 2017-10-09 | 2020-09-04 | 罗兹制药公司 | 药物树脂化物组合物及其制备和使用方法 |
| AU2019383389A1 (en) * | 2018-11-19 | 2021-05-06 | Jazz Pharmaceuticals Ireland Limited | Alcohol-resistant drug formulations |
| EP3930702A1 (en) | 2019-03-01 | 2022-01-05 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| TW202139986A (zh) | 2020-02-21 | 2021-11-01 | 愛爾蘭商爵士製藥愛爾蘭有限責任公司 | 治療原發性嗜睡症之方法 |
| KR20230071228A (ko) | 2021-11-16 | 2023-05-23 | 김명진 | 가상공간에 사용자가 마시는 주류를 적용하기 위한 방법 및 장치 |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4293539A (en) | 1979-09-12 | 1981-10-06 | Eli Lilly And Company | Controlled release formulations and method of treatment |
| GB9104854D0 (en) | 1991-03-07 | 1991-04-17 | Reckitt & Colmann Prod Ltd | Sustained release compositions |
| US5656295A (en) | 1991-11-27 | 1997-08-12 | Euro-Celtique, S.A. | Controlled release oxycodone compositions |
| US5266331A (en) | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
| US5585115A (en) | 1995-01-09 | 1996-12-17 | Edward H. Mendell Co., Inc. | Pharmaceutical excipient having improved compressability |
| SE9600070D0 (sv) * | 1996-01-08 | 1996-01-08 | Astra Ab | New oral pharmaceutical dosage forms |
| US6696088B2 (en) | 2000-02-08 | 2004-02-24 | Euro-Celtique, S.A. | Tamper-resistant oral opioid agonist formulations |
| CN2423892Y (zh) * | 2000-04-30 | 2001-03-21 | 尹为民 | 分隔式药物胶囊 |
| EP1389092B1 (en) | 2001-05-11 | 2006-11-15 | Endo Pharmaceuticals Inc. | Abuse-resistant opioid dosage form |
| AU2002323032B2 (en) * | 2001-08-06 | 2005-02-24 | Euro-Celtique S.A. | Opioid agonist formulations with releasable and sequestered antagonist |
| AR040588A1 (es) | 2002-07-26 | 2005-04-13 | Schering Corp | Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa |
| US20040202717A1 (en) | 2003-04-08 | 2004-10-14 | Mehta Atul M. | Abuse-resistant oral dosage forms and method of use thereof |
| DE10353186A1 (de) | 2003-11-13 | 2005-06-16 | Röhm GmbH & Co. KG | Mehrschichtige Arzneiform, enthaltend eine in Bezug auf die Wirkstoffabgabe modulatorisch wirkende Substanz |
| DE10353196A1 (de) | 2003-11-13 | 2005-06-16 | Röhm GmbH & Co. KG | Mehrschichtige Arzneiform mit einer die Abgabe einer modulatorischen Substanz beeinflussenden Matrix |
| US7201920B2 (en) | 2003-11-26 | 2007-04-10 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of opioid containing dosage forms |
| EP1755556A4 (en) | 2004-05-04 | 2009-09-30 | Innophos Inc | DIRECTLY COMPRESSIBLE TRICALCIUM PHOSPHATE |
| DK2526932T3 (en) | 2006-06-19 | 2017-07-17 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
| JP2010506833A (ja) * | 2006-10-11 | 2010-03-04 | アルファーマ，インコーポレイテッド | 医薬組成物 |
| US8623418B2 (en) * | 2007-12-17 | 2014-01-07 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
| CA2709905A1 (en) * | 2007-12-17 | 2009-06-25 | Alfred Liang | Abuse-resistant oxycodone composition |
| CN101461809A (zh) * | 2007-12-18 | 2009-06-24 | 重庆药友制药有限责任公司 | 一种泮托拉唑钠肠溶片及其制备方法 |
| RU2541159C2 (ru) * | 2010-10-26 | 2015-02-10 | АЛФАРМА ФАРМАСЬЮТИКЭЛЗ, ЭлЭлСи | Композиции и способы для смягчения дыхательной недостаточности, вызванной передозировкой опиоидов |
-
2012
- 2012-01-25 US US13/982,890 patent/US20140141090A1/en not_active Abandoned
- 2012-01-25 MX MX2013008225A patent/MX2013008225A/es unknown
- 2012-01-25 KR KR1020137023085A patent/KR20130124551A/ko not_active Ceased
- 2012-01-25 CN CN2012800076033A patent/CN103415285A/zh active Pending
- 2012-01-25 EP EP12704131.7A patent/EP2670400A1/en not_active Withdrawn
- 2012-01-25 KR KR1020167005412A patent/KR20160031038A/ko not_active Ceased
- 2012-01-25 AU AU2012213056A patent/AU2012213056A1/en not_active Abandoned
- 2012-01-25 WO PCT/IB2012/050348 patent/WO2012104752A1/en not_active Ceased
- 2012-01-25 KR KR1020187006298A patent/KR20180027641A/ko not_active Ceased
- 2012-01-25 JP JP2013552292A patent/JP2014504630A/ja not_active Withdrawn
- 2012-01-25 SG SG2013052188A patent/SG191872A1/en unknown
- 2012-01-25 KR KR1020197002897A patent/KR20190014577A/ko not_active Ceased
- 2012-01-25 RU RU2013136350/15A patent/RU2013136350A/ru not_active Application Discontinuation
- 2012-01-25 CA CA2824835A patent/CA2824835A1/en not_active Abandoned
- 2012-01-25 BR BR112013019431-6A patent/BR112013019431A2/pt not_active IP Right Cessation
-
2013
- 2013-07-08 ZA ZA2013/05108A patent/ZA201305108B/en unknown
- 2013-08-01 IL IL227770A patent/IL227770A0/en unknown
-
2016
- 2016-02-04 AU AU2016200708A patent/AU2016200708A1/en not_active Abandoned
- 2016-12-07 JP JP2016237476A patent/JP2017081942A/ja not_active Withdrawn
-
2017
- 2017-07-07 AU AU2017204639A patent/AU2017204639A1/en not_active Abandoned
-
2018
- 2018-03-07 JP JP2018040441A patent/JP2018109059A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014504630A5 (cg-RX-API-DMAC7.html) | ||
| RU2013136350A (ru) | Фармацевтическая композиция, содержащая опиоидный агонист и секвестрированный антагонист | |
| JP2011137020A5 (cg-RX-API-DMAC7.html) | ||
| AR089645A1 (es) | Particula multicapas de sabor enmascarado, metodo, uso, composicion farmaceutica | |
| JP2016514165A5 (cg-RX-API-DMAC7.html) | ||
| JP2013151541A5 (cg-RX-API-DMAC7.html) | ||
| RU2013117274A (ru) | Композиции и способы для смягчения дыхательной недостаточности, вызванной передозировкой опиоидов | |
| JP2015044834A5 (cg-RX-API-DMAC7.html) | ||
| HRP20150369T1 (hr) | Novi farmaceutski pripravak otporan na zlouporabu za tretiranje zavisnosti o opioidima | |
| BRPI0908942A2 (pt) | Sistemas de distribuição de fármacos compreendendo fármacos fracamente básicos e ácidos orgânicos | |
| JP2015521988A5 (cg-RX-API-DMAC7.html) | ||
| AR079862A1 (es) | Composicion de topiramato con sabor enmascarado, un comprimido desintegrable oralmente que comprende la misma y metodo de preparacion | |
| EA201491164A1 (ru) | Трансдермальная система доставки | |
| JP2008280351A5 (cg-RX-API-DMAC7.html) | ||
| JP2015091825A5 (cg-RX-API-DMAC7.html) | ||
| JP2018514523A5 (cg-RX-API-DMAC7.html) | ||
| WO2007111945A3 (en) | Method for management of diarrhea | |
| JP7399949B2 (ja) | 非アルコール性脂肪性肝炎治療のための組成物及び方法 | |
| RU2011104146A (ru) | Фармацевтическая композиция, содержащая опиоидный антагонист, для лечения задержки мочи | |
| JP2013508289A5 (cg-RX-API-DMAC7.html) | ||
| JP2012082195A5 (cg-RX-API-DMAC7.html) | ||
| JP2013514979A5 (cg-RX-API-DMAC7.html) | ||
| RU2017122758A (ru) | Композиции, содержащие 15-hepe, и способы лечения или предотвращения фиброза с применением указанных композиций | |
| EA201590474A1 (ru) | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ОСНОВЕ КОМПОЗИТНЫХ КАПСУЛ, ВКЛЮЧАЮЩИХ ИРБЕСАРТАН И ИНГИБИТОР ГМГ-КоА РЕДУКТАЗЫ | |
| WO2016091805A3 (de) | Naloxon-monopräparat und mehrschichttablette |